Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.
The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs includes 5-HT3 Inhibitors, NK1 Inhibitors and others. The proportion of 5-HT3 Inhibitors in 2017 is about 62%, and the proportion of NK1 Inhibitors in 2017 is about 33%.
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs are application for Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy and others. The most of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs is used for Moderately Emetogenic Chemotherapy, and the market share of that is about 52 % in 2017.
Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-chemotherapy-induced-nausea-vomiting-drugs-2019-2024-58
According to this study, over the next five years the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market will register a 5.9% CAGR in terms of revenue, the global market size will reach US$ 96 million by 2024, from US$ 72 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Chemotherapy Induced Nausea and Vomiting (CINV) Drugs business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by product type, application, key manufacturers and key regions and countries.
This study considers the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
- 5-HT3 Inhibitors
- NK1 Inhibitors
- Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
- Highly Emetogenic Chemotherapy
- Moderately Emetogenic Chemotherapy
- Low Emetogenic Chemotherapy
- Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Spain
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
- Merck
- Eisai
- Mundipharma
- Qilu Pharma
- Teva
- Novartis
- Heron Therapeutics
- Roche
- Mylan
- Tesaro
Research objectives:
- To study and analyze the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
- To understand the structure of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by identifying its various subsegments.
- Focuses on the key global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
- To analyze the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
- To project the consumption of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs submarkets, with respect to key regions (along with their respective key countries).
- To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
- To strategically profile the key players and comprehensively analyze their growth strategies.
Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-chemotherapy-induced-nausea-vomiting-drugs-2019-2024-58
Table of content
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption 2014–2024
2.1.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption CAGR by Region
2.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Type
2.2.1 5-HT3 Inhibitors
2.2.2 NK1 Inhibitors
2.2.3 Other
2.3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption by Type
2.3.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Market Share by Type (2014–2019)
2.3.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Revenue and Market Share by Type (2014–2019)
2.3.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sale Price by Type (2014–2019)
2.4 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Application
2.4.1 Highly Emetogenic Chemotherapy
CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170 / +91 8087042414
Email: [email protected]
Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/
Chemotherapy-Induced Nausea and Vomiting Therapeutics Market report published by Value Market Research, which studies the future outlook of the market.
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the chemotherapy-induced nausea and vomiting therapeutics market include GlaxoSmithKline plc, Merck & Co., Inc, Teva Pharmaceuticals, Heron Therapeutics, Inc., F. Hoffmann-La Roche AG, Tesaro, Inc., Acacia Pharma, Baxter international Inc., Lee's Pharmaceutical Holdings, Mundipharma International limited, Kyowa Hakko Kirin Co., Ltd.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/chemotherapy-induced-nausea-and-vomiting-therapeutics-market/download-sampleMarket DynamicsRising cancer prevalence, a growing number of patients undergoing chemotherapy, expanding healthcare infrastructure, and a high success rate of therapies are factors accelerating the demand for nausea and vomiting drugs induced by chemotherapy.
As per World Health Organization (WHO) estimates, cancer is a leading cause of death worldwide, accounting for nearly 10 million new cases in 2020.
Easing the health insurance process, expanding the number of cancer specialist hospitals worldwide, and growing life expectancy is causing a rise in the number of chemotherapies performed, propelling the market growth.
The global Chemotherapy-Induced Nausea and Vomiting Drugs market is segmented by company, region (country), by Type, and by Application.
Players, stakeholders, and other participants in the global Chemotherapy-Induced Nausea and Vomiting Drugs market will be able to gain the upper hand as they use the report as a powerful resource.
The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by TypeDownload FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-chemotherapyinduced-nausea-vomiting-drugs-2021-715 Existing DrugsAkynzeo (Netupitant-Palonosetron FDC)Aloxi (Palonosetron)Emend (Aprepitant)Kytril Generic (Granisetron)Zofran Generic (Ondansetron)Pipeline DrugsSUSTOL (Granisetron Injection extended release)Rolapitant Segment by Application Serotonin Receptor AntagonistsNK1 Receptor Antagonists The Chemotherapy-Induced Nausea and Vomiting Drugs market is analysed and market size information is provided by regions (countries).
Segment by Application, the Chemotherapy-Induced Nausea and Vomiting Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company Merck & Co., Inc.GlaxoSmithKline plcTesaro, Inc.Helsinn GroupF.
The global Chemotherapy-Induced Nausea and Vomiting Drugs Market report offers a comprehensive assessment of the market for the forecast years.
The key market players for the global Chemotherapy-Induced Nausea and Vomiting Drugs market are listed below: Helsinn Heron Therapeutics Merck & Co Tesaro Acacia Pharma Aphios Barr Laboratories Baxter Healthcare Eisai Especificos Stendhal F.Hoffmann La Roche Mundipharma Mylan Pharmaceuticals OPKO Health Orchid Healthcare OthersClick here to get a FREE Sample Copy of the Chemotherapy-Induced Nausea and Vomiting Drugs Market Research Report @ https://www.decisiondatabases.com/contact/download-sample-30459The Global Chemotherapy-induced Nausea and Vomiting Drugs Market Report is equipped with market data from 2016 to 2026.
It also evaluates the competitive scenario of the leading players.
The detailed sales channel is also covered in the study.COVID-19 Impact Analysis on Chemotherapy-Induced Nausea and Vomiting Drugs MarketThe global pandemic COVID-19 has affected the Chemotherapy-induced Nausea and Vomiting Drugs market directly or indirectly.
The impact study on production, supply-demand, and sales provides a holistic approach to the future.Do You Have Any Query Or Report Customization?
Ask Our Market Expert @ https://www.decisiondatabases.com/contact/ask-questions-30459Why Purchase this Report?A robust research methodology has been followed to collect data for the report.
